diafer 50 mg/ml injektionsvæske, opløsning
pharmacosmos a/s - ferriderisomaltose - injektionsvæske, opløsning - 50 mg/ml
trimopan 100 mg filmovertrukne tabletter
orion corporation - trimethoprim - filmovertrukne tabletter - 100 mg
trimopan 10 mg/ml oral suspension
orion corporation - trimethoprim - oral suspension - 10 mg/ml
trimethoprim "orifarm" 100 mg filmovertrukne tabletter
orifarm a/s - trimethoprim - filmovertrukne tabletter - 100 mg
daivonex 50 mikrogram/g creme
leo pharma a/s - calcipotriolmonohydrat - creme - 50 mikrogram/g
daivonex 50 mikrogram/ml kutanopløsning
leo pharma a/s - calcipotriol - kutanopløsning - 50 mikrogram/ml
turret 90 emulsionskoncentrat
globachem nv - metconazol - emulsionskoncentrat - 90 g/l metconazol
primus 250 wg vanddispergerbart granulat
dow agrosciences danmark a/s - florasulam - vanddispergerbart granulat - 250 g/kg florasulam
azuleo suspensionskoncentrat
isk biosciences products inc. - cyazofamid - suspensionskoncentrat - 160 g/l cyazofamid
cosentyx
novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - immunosuppressiva - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriasis arthritiscosentyx, alene eller i kombination med methotrexat (mtx), er indiceret til behandling af aktiv psoriasis artrit hos voksne patienter, når svar på tidligere sygdomsmodificerende anti-reumatiske lægemidler (dmard) behandling har været mangelfuld. aksial spondyloarthritis (axspa)ankyloserende spondylitis (som, røntgen aksial spondyloarthritis)cosentyx er indiceret til behandling af aktiv ankyloserende spondylitis i voksne, der har reageret tilstrækkeligt til konventionel behandling. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.